AbbVie Buys Apogee
AbbVie is acquiring Apogee Therapeutics, a biotech company developing an experimental eczema drug, for $10.9 billion
Apogee Therapeutics, which is developing a promising atopic dermatitis drug, saw its stock close nearly 47% higher on Monday.